Navigating the oncology patent cliff: Strategic imperatives for big pharma

Key cancer drugs lose exclusivity soon—who’s ready to withstand the oncology patent cliff?

By Andreas Dimakakos, Director of Scientific Insights, PhD, MBA, PMP ; and Elena Hilario Martinez, Customer Success Associate • Aug. 18, 2025

Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

By BioPharma Dive staff • Aug. 15, 2025

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Merck KGaA ventures into new territory in the US

Miguel Fernández Alcalde, head of Merck KGaA’s U.S. arm, aims to “double down” on innovation. The company’s recent SpringWorks deal is just a start.

By Alexandra Pecci • Aug. 15, 2025

Pfizer looks to expand ADC use after positive bladder cancer data

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify for chemotherapy.

By Jonathan Gardner • Aug. 12, 2025

Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

By BioPharma Dive staff • Aug. 12, 2025

Novartis drug acquired in Morphosys deal succeeds against tough-to-treat autoimmune disease

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a multibillion-dollar deal that hadn’t yet paid dividends.

By Ben Fidler • Aug. 11, 2025

Regulatory uncertainty and access challenges changing go-to-market models, DTC, and DTP

DTC isn’t converting to Rxs at the pharmacy. Learn how access may be key to your brand’s success.

Aug. 11, 2025

Elevidys sales weaken; Neumora gets into obesity

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

By BioPharma Dive staff • Aug. 8, 2025

Inside AstraZeneca’s long-term strategy in lung cancer

Decades-long research has yielded a strong and growing franchise built around drugs for a genetic form of lung cancer.

By Michael Gibney • Aug. 8, 2025

Lilly shares fall as obesity pill misses expectations in key trial

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts anticipated, leading to a selloff in shares that erased about $100 billion in market value. 

By Jonathan Gardner • Aug. 7, 2025

Novo pushes back against obesity drug compounders as competition intensifies

The company hopes an important CVS deal and broader legal action against the makers of knockoff Wegovy can solidify its slipping position in the lucrative market for weight loss drugs.

By Jonathan Gardner • Aug. 6, 2025

Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share

The company formerly known a Sosei Heptares unveiled new weight loss programs. Elsewhere, BridgeBio and Madrigal unveiled sales numbers for their chief drugs.

By BioPharma Dive staff • Aug. 6, 2025

US biotech needs government support to match China’s gains, Pfizer CEO says

“The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors in Aug. 5 comments on China’s rising competitiveness.

By Ben Fidler • Aug. 5, 2025

Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to-consumer options.

By Ned Pagliarulo • Aug. 5, 2025

Trump threatens up to 250% tariffs on pharma imports

The president said he would first install a “small tariff” on pharmaceutical goods before ratcheting up the rate over the next year and a half.

By Philip Neuffer • Aug. 5, 2025

Regeneron cancer bispecific rejected again; Allogene discloses trial death

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

By BioPharma Dive staff • Aug. 1, 2025

Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA approvals.

By Ned Pagliarulo • July 30, 2025

Merck plans spending shift to boost business beyond Keytruda

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support of newer drugs and R&D.

By Jonathan Gardner • July 29, 2025

Novo cuts guidance, names new CEO as obesity drug challenges mount

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its competition with rival Eli Lilly.

By Ned Pagliarulo • July 29, 2025

GSK pays $500M to enter drugmaking alliance with Hengrui

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines and be worth $12 billion.

By Ben Fidler • July 28, 2025

Redefining commercial success in specialty lite with alternative channels

The optimal commercial strategy for specialty-lite brands – alternative channels to drive unparalleled commercial outcomes.

July 28, 2025

FDA delays approval decision for Bayer menopause therapy

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the U.K. have already cleared it for use.

By Delilah Alvarado • July 25, 2025

Bristol Myers shuffles its executive ranks with new CMO

AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit Hirawat, on Aug. 1.

By Gwendolyn Wu • July 25, 2025

Rocket lays off staff; Abivax capitalizes on immune drug data

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

By BioPharma Dive staff • July 24, 2025

AstraZeneca drug acquired in Alexion deal succeeds in autoimmune disease trial

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells for myasthenia gravis.

By Ben Fidler • July 24, 2025